Murata Hiroto, Okonogi Noriyuki, Wakatsuki Masaru, Kato Shingo, Kiyohara Hiroki, Karasawa Kumiko, Ohno Tatsuya, Nakano Takashi, Kamada Tadashi, Shozu Makio, The Working Group Of Gynecological Tumors The Working Group Of Gynecological
QST Hospital, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan.
Cancers (Basel). 2019 Apr 4;11(4):482. doi: 10.3390/cancers11040482.
Surgical resection is considered a standard therapy for malignant melanoma (MM). However, it has not yet been established as an optimal treatment strategy for gynecological MMs, particularly owing to their very low incidence rates. We retrospectively analyzed clinical outcomes of carbon-ion radiotherapy (C-ion RT) for gynecological MMs. The eligibility criterion was the presence of histologically confirmed gynecological MM. Patients with pelvic or inguinal lymph node metastases were included, while those with distant metastases were excluded. The pelvic and inguinal lymph node regions were irradiated with up to 36 gray relative biological effectiveness (Gy (RBE)) followed by a gross tumor volume boost of up to 57.6 Gy (RBE) or 64 Gy (RBE) in 16 fractions over 4 weeks. Thirty-seven patients (median age: 71 years) were examined. In total, 22 patients had vaginal tumors, 12 had vulval tumors, and 3 had cervical uterine tumors. The median follow-up periods were 23 months (range: 5-103 months) for all patients and 53 months (range: 16-103 months) for survivors. Thirty of 37 patients (81%) achieved complete tumor disappearance. The 2-year local control, overall survival, and progression-free survival rates were 71%, 53%, and 29%, respectively. C-ion RT may be a definitive treatment option for patients with gynecological MM.
手术切除被认为是恶性黑色素瘤(MM)的标准治疗方法。然而,对于妇科MM,它尚未被确立为最佳治疗策略,特别是由于其发病率极低。我们回顾性分析了碳离子放疗(C离子RT)治疗妇科MM的临床结果。纳入标准是组织学确诊的妇科MM。包括盆腔或腹股沟淋巴结转移的患者,排除远处转移的患者。盆腔和腹股沟淋巴结区域接受高达36格雷相对生物效应(Gy(RBE))的照射,随后对大体肿瘤体积进行增强照射,在4周内分16次给予高达57.6 Gy(RBE)或64 Gy(RBE)。检查了37例患者(中位年龄:71岁)。总共有22例患者患有阴道肿瘤,12例患有外阴肿瘤,3例患有宫颈子宫肿瘤。所有患者的中位随访期为23个月(范围:5 - 103个月),幸存者为53个月(范围:16 - 103个月)。37例患者中有30例(81%)实现肿瘤完全消失。2年局部控制率、总生存率和无进展生存率分别为71%、53%和29%。C离子RT可能是妇科MM患者的一种确定性治疗选择。